Stay updated with breaking news from Csl vifor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data from Spherix Global Insights second annual EU IgAN patient chart audit indicates that even with the EMA approval of FILSPARITM (sparsentan),. ....
CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Medicines Agency's (EMA) CHMP has recommended approval of sparsentan for the treatment of adults with primary IgAN with a urine protein excretion >1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). IgAN is a rare kidney disorder and a leading cause of kidney failure. The CHMP opinion provides the basis for the European Commission's final decision regarding CMA for sparsentan. If approved in Europe ....